{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(5)"],"submitter":["Ho GYF"],"pubmed_abstract":["<h4>Background</h4>Most studies associating circulating tumor DNA (ctDNA) with outcome in lung cancer treatment were either cross-sectional or, if longitudinal, only analyzed a limited number of genes. This study evaluated the potential of utilizing ctDNA profiled by a panel of common cancer genes to monitor tumor burden and to reveal molecular characteristics of tumor along treatment course.<h4>Methods</h4>Twenty Chinese non-small cell lung cancer (NSCLC) patients with serial plasma samples collected (I) before starting on either first- or second-line treatment, (II) at stable disease on treatment, and (III) upon disease progression, were analyzed for mutations in ctDNA using the PGDx 64-gene panel. Paired statistics compared mutation profiles between any two of the three time points.<h4>"],"journal":["Translational lung cancer research"],"pagination":["1873-1884"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7653134"],"repository":["biostudies-literature"],"pubmed_title":["Longitudinal multi-gene panel assessment of circulating tumor DNA revealed tumor burden and molecular characteristics along treatment course of non-small cell lung cancer."],"pmcid":["PMC7653134"],"pubmed_authors":["Guzman M","Ho GYF","Ip MSM","Wang T","Kwok HH","Lam DCL","Rasul R","Peila R"],"additional_accession":[]},"is_claimable":false,"name":"Longitudinal multi-gene panel assessment of circulating tumor DNA revealed tumor burden and molecular characteristics along treatment course of non-small cell lung cancer.","description":"<h4>Background</h4>Most studies associating circulating tumor DNA (ctDNA) with outcome in lung cancer treatment were either cross-sectional or, if longitudinal, only analyzed a limited number of genes. This study evaluated the potential of utilizing ctDNA profiled by a panel of common cancer genes to monitor tumor burden and to reveal molecular characteristics of tumor along treatment course.<h4>Methods</h4>Twenty Chinese non-small cell lung cancer (NSCLC) patients with serial plasma samples collected (I) before starting on either first- or second-line treatment, (II) at stable disease on treatment, and (III) upon disease progression, were analyzed for mutations in ctDNA using the PGDx 64-gene panel. Paired statistics compared mutation profiles between any two of the three time points.<h4>","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Oct","modification":"2025-04-19T23:40:17.099Z","creation":"2025-04-19T23:40:17.099Z"},"accession":"S-EPMC7653134","cross_references":{"pubmed":["33209609"],"doi":["10.21037/tlcr-20-675"]}}